Onkologie. 2011:5(4):207-209

Cytokines in treating metastatic renal cell carcinoma: past and present

Michaela Zezulová, Bohuslav Melichar
Onkologická klinika LF UP a FN Olomouc

The article summarizes the use of cytokines in treating metastatic renal cell carcinoma from the time when, given the radioresistant

and chemoresistant properties of renal cell carcinoma, they were virtually the only systemic therapy until present day when they give

way and are being replaced with new biological agents, such as tyrosine kinase inhibitors or mTOR inhibitors. It is only interferon-α in

combination with bevacizumab (a monoclonal antibody against VEGF) that has retained its position as one of the therapeutic options

in the first-line treatment for mRCC. The article also deals with the mechanisms of effects of cytokines, including adverse effects that

limit the use of this treatment.

Keywords: carcinoma, kidney, cytokines, interferon, interleukin-2

Published: December 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zezulová M, Melichar B. Cytokines in treating metastatic renal cell carcinoma: past and present. Onkologie. 2011;5(4):207-209.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Fiala R, Všetička J. Laparoskopická ručně asistovaná resekce ledvin za využití radiofrekveční koagulace. Ces Urol 2008; 12(2): 117 Abstract 60.
    2. Hartmann I, Študent V, Grepl M, Hrabec M, Vidlář A. Laparoskopická nefrektomie - zlatý standard? Ces Urol 2008; 12(2): 116 Abstract 58.
    3. Ravaud A, Audhuy B, Gomez F, et al. Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Francais d´Immunotherapie. J Clin Oncol 1998; 16: 2728-2732. Go to original source... Go to PubMed...
    4. Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 2008; 20: 303-321. Go to original source...
    5. Mickisch GH, Roehrich K, Koessig J, Forster S, Tschada RK, Alken PM. 1990. Mechanisms and modulation of multidrug resistance in primary human renal cell carcinoma. J Urol 144: 755-759. Go to original source... Go to PubMed...
    6. Motzer RI, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289-296. Go to original source... Go to PubMed...
    7. Medical-Research-Council-Renal-Cancer-Collaborators. 1999. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 353: 14-17. Go to original source...
    8. Atzpodien J, Kirchner H, Illiger HJ, Metzner B, Ukena D, Schott H, Funke PJ, Gramatzki M, von Jurgenson S, Wandert T, Patzelt T, Reitz M. 2001. IL-2 in combination with IFN-alfa and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 85: 1130-1136. Go to original source... Go to PubMed...
    9. Melichar B. How Can Second-Line Therapy for Metastatic Renal Cell Carcinoma Help to Define an Overall Management Strategy? Oncology 2009; 77: 82-91. Go to original source... Go to PubMed...
    10. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13: 688-696. Go to original source... Go to PubMed...
    11. Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Fyfe G. High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J Sci Am 1997; 3: S70-S72. Go to PubMed...
    12. Murray Law T, Motzer RJ, Mazumdar M, Sell KW, Walther PJ, O Connell M, Khan A, Vlamis V, Vogelzang NJ, Bajorin DF. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 1995; 76: 824-832. Go to original source...
    13. Ravaud A, Trufflandier N, Ferriere JM, Debled M, Palussiere J, Cany L, Gaston R, Mathoulin-Pelissier S, Bui BN. Subcutaneous interleukin-2, interferon -2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial. Br J Cancer 2003; 89: 2213-2218. Go to original source... Go to PubMed...
    14. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CPG, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 133-141. Go to original source... Go to PubMed...
    15. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21: 3127-3132. Go to original source... Go to PubMed...
    16. Williams BRG. Interferon-alfa and -beta: Basic principles and preclinical studies: In: Principles and Practice of the Biologic Therapy of Cancer (Rosenberg SAs, eds). Philadelphia, Lippincott Williams and Wilkins, 2000: 194-208.
    17. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000; 163: 408-417. Go to original source... Go to PubMed...
    18. Wirth MP. Immunotherapy for metastatic renal cell carcinoma. Urol Clin N Am 1993; 20: 283-295. Go to original source...
    19. Medical Research Council Renal Cancer Collaborators, Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial, Lancet 353 (1999) (9146), pp. 14-17. Go to original source...
    20. Negrier S, Petrol D, Ravaud A, et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patiens with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 2007; 110: 2468-2477. Go to original source... Go to PubMed...
    21. Motzer RJ, Rakhit A, Ginsberg M, Rittweger K, Vuky J, Yu R, Fettner S, Hooftman L. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma. J Clin Oncol 2001; 19: 1312-1319. Go to original source... Go to PubMed...
    22. Escudier B, Chevreau C, Lasset C, Douillard JY, Ravaud A, Fabbro M, Caty A, Ross JF, Viens P, Bergerat JP, Savary J, Negrier S. Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? J Clin Oncol 1999; 17: 2039-2043. Go to original source... Go to PubMed...
    23. Kolombo I, Kříž R, Vymazal J, et al. Karcinom ledviny - současná situace a integrace miniinvazivních technik (vertebroplastiky, cementoplastiky, selektivní embolizace a radiofrekvenční ablace), biologické a konvenční chirurgické léčby. Urolog. pro Praxi 2011; 12(2): 80-90.

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.